Global LAG 3 Inhibitor Market Research Report 2022-2028 Featuring Key Players

DublinAnd Jan 31 2022 /PRNewswire/ – Added “Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028” report to ResearchAndMarkets.com Show.

The emerging direction of LAG-3 next-generation immunotherapies with the ongoing advances movement combined with new emerging technologies to develop targeted therapies argues for hope for better alternative therapies during the prediction period.

The increasing burden of critical diseases such as cancer, leukemia, lymphoma and muscular degeneration are the main factors promoting the adoption of LAG3-targeting drugs among the global population. Moreover, the rise in the number of pharmaceuticals being produced through pipelines and the high growth potential in untapped emerging economies is expected to open up new opportunities for market players in the future.

Major players in the market include MacroGenics, costume laband Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, and others.

Cancer immunotherapy is a new approach that can reverse tumor immune escape by suppressing immune checkpoint pathways. Several immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death-1 (PD-1) and apoptosis ligand-1 (PD-L1) have shown sustained efficacy against melanoma, kidney, lung and other cancers.

However, despite these promising long-term responses, the majority of patients failed to respond to immune checkpoint blockade, indicative of primary resistance. In addition, many of those patients who initially responded to treatment experience a relapse secondary to acquired resistance.

To mitigate these challenges, researchers have identified several co-stimulatory receptors including the lymphocyte activating gene-3 (LAG-3). LAG-3 is a member of the immunoglobulin (IgSF) family and exerts a variety of biological effects on T cell function. It is expressed on the membranes of natural killer (NK) cells, tumor infiltrating lymphocytes (TIL), a subset of T cells, and dendritic cells.

In addition to its role in a wide range of autoimmune diseases, it also reduces the body’s ability to fight infection and promote chronic inflammation. Apart from this, the receptor is also overexpressed in many cancers including breast cancer, melanoma, non-Hodgkin’s lymphoma, myeloma, gastric cancer, and others.

The receptor is considered a promising target in cancer immunotherapy. Studies have shown that LAG-3 has a synergistic effect with PD-1 and PD-L1. Although the exact mechanism is unclear, its modification has been shown to cause a negative regulatory effect on T-cell function, preventing tissue damage and autoimmunity.

LAG-3 and PD-1 are often co-expressed and up-regulated on tumor infiltrating lymphocytes (TILs) resulting in immune depletion and tumor growth. Inactivation of LAG-3 not only improves anti-tumor immune responses but also potentiates other forms of immunotherapy due to its different mechanism of action which is primarily mediated by impeding cell cycle progression.

At present, researchers have developed two inhibitory approaches including LAG-3 Ig fusion proteins (IMP321) and LAG-3 that target antibodies. IMP321 developed by Immutep is soluble forms of LAG-3 that regulate co-stimulatory molecules and increase production of interleukin (IL)-12 to enhance tumor immune responses.

Several monoclonal antibodies targeting LAG-3 have been developed that interfere with the interaction of LAG-3 between major histocompatibility-II molecules expressed by tumor or immune cells, promoting apoptosis of tumor cells. To enhance the efficacy of LAG-3-targeted drugs, the researchers also created several bispecific antibodies that enhanced efficacy, specificity, and cost-effectiveness.

There are more than 100 ongoing clinical trials of 35 drugs, which evaluate the role of LAG-3 inhibitors in a wide range of cancers. Developed by Bristol Myers Squibb, Relatlimab is a promising LAG-3 target antibody that has been granted priority review by the U.S. Food and Drug Administration for the management of melanoma in combination with Nivolumab.

The drug is expected to enter the market by 2022, revolutionizing the cancer treatment paradigm. Apart from this, several preclinical studies are also evaluating the role of LAG-3 in other therapeutic indications including diabetes, multiple sclerosis, HIV, Parkinson’s disease, and other autoimmune disorders.

Highlights of Clinical Trials on Global LAG 3 Inhibitors and Market Opportunities in 2028 Report:

  • Global market dynamics of LAG 3 inhibitors
  • Clinical approaches to targeting LAG 3 . inhibitors
  • Number of LAG3-inhibiting drugs in trials
  • Patent Approved LAG 3 Inhibitor
  • LAG 3 inhibitor trials by stage, company, country, indicator
  • Company/Partnership/Deals Agreement for Ongoing Trials
  • Targeted approach to LAG-3 in cancer treatment
  • Therapeutic approaches to the new targeted therapy LAG-3
  • Future Outlook of the Global LAG3 Inhibitor Market

Main topics covered:

1. Introduction to LAG-3 inhibitor
1.1 Overview
1.2 Historical Perspective

2. Targeted approach to LAG-3 in cancer treatment

3. LAG-3 as a therapeutic target in Parkinson’s disease
3.1 LAG-3 in progress PD
3.2 LAG-3 as a potential biomarker for PD

4. The role of LAG-3 in viral infections

5. LAG-3 as a potential target in autoimmune diseases

6. LAG3 Inhibitor – Mechanism of Action

7. Therapeutic approaches to the new targeted therapy LAG-3
7.1 Fusion proteins
7.2 Monoclonal antibodies
7.3 Bispecific antibodies

8. Overview of the global clinical trials of the LAG-3 inhibitor
8.1 by the company
8.2 by country
8.3 by reference
8.4 by patient sector
8.5 by stage

9. Global LAG-3 Inhibitor Clinical Trials Insight 2028
9.1 Search
9.2 Preclinical
9.3 First stage
9.4 1st / 2nd stage
9.5 second stage
9.6 Second / Third Stage
9.7 Pre-registration

10. LAG-3 inhibitor global market
10.1 Current Market Scenario
10.2 Assessing Market Opportunities

11. Eftilagimod Alpha – Patent Insights
11.1 United States
11.2 Europe
11.3 Japan
11.4 Rest of the world

12. Relatlimab – Food and Drug Administration (FDA) Designated LAG3 Inhibitor

13. Global market dynamics for LAG3 inhibitors
13.1 Market Drivers
13.2 Marketing Challenges

14. The future of the global LAG3 inhibitor market

15. Competitive landscape

  • Avacta
  • Bristol Myers Squibb
  • F-Star Treatments
  • GlaxoSmithKline
  • Imotip
  • invent
  • macrogine
  • merck
  • Nanobiotics
  • Novartis
  • Symphogen

For more information on this report, visit https://www.researchandmarkets.com/r/vnkjd0

Media contact:

Research and Markets
Laura Wooddirector, mentor
[email protected]

For EST office hours, call +1-917-300-0470
For US/Canada, call toll free +1-800-526-8630
For GMT office hours, call +353-1-416-8900

US Fax: 607-646-1904
Fax (outside the US): +353-1-481-1716

SOURCE Research & Markets

.

Leave a Comment